Receptor reagent for detecting novel coronavirus neutralizing antibodies and its application
By coating the new coronavirus RBD protein on the receptor microspheres and binding to the human ACE2 protein, the new coronavirus neutralizing antibodies are detected by nanophoto-excitation method, which solves the problem of insufficient detection complexity and sensitivity in the prior art. Fast and accurate neutralizing antibody detection is achieved.
Patent Information
- Application Number
- CN202110220408.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-13
- Filing Date
- 2021-02-26
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-02-26
AI Technical Summary
Among the existing methods of novel coronavirus detection, nucleic acid detection is complex and difficult to be carried out in general laboratories. It lacks simple, high sensitivity and high specific neutralizing antibody detection tools. Clinical laboratories need a fast and accurate in vitro diagnostic reagent. Box to detect new coronavirus neutralizing antibodies.
The receptor microspheres containing the RBD protein of the novel coronavirus were used to bind to human ACE2 protein, and neutralizing antibodies were detected by nanophoto-excitation method to simulate the process of RBD protein entering the cell. The principle of competition method was used to detect detectable Chemiluminescence signal, judge the presence of the antibody based on the signal suppression rate.
It has achieved rapid, high sensitivity and strong specificity of novel coronavirus neutralizing antibody detection, suitable for large-scale sample detection, accurate test results, and can report results within 30 minutes, with a large throughput, which is suitable for large-scale sample detection.
Smart Images

Figure CN113391064B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of immunoassay detection, and specifically relates to a receptor reagent for detecting neutralizing antibodies against the novel coronavirus and its application. Background Art
[0002] SARS-CoV-2 is a new coronavirus of the genus Betavirus in the family Coronaviridae, and is adjacent to the SARS-CoV group on the evolutionary tree. Studies have found that SARS-CoV-2 has four main structural proteins: spike protein (S), nucleocapsid protein (N), membrane protein (M), and envelope protein (E).
[0003] "Nucleocapsid protein (N)" is the most abundant protein in coronaviruses. During the assembly of the virion, the N protein binds to the viral RNA and leads to the formation of a helical nucleocapsid. The nucleocapsid protein is a highly immunogenic phosphoprotein that is associated with viral genome replication and regulation of cell signaling pathways. Due to the sequence conservation of the N protein (94% homology with SARS) and its strong immunogenicity, the N protein is often used as a diagnostic test tool for coronaviruses. "Spike protein (S)" is the most important surface membrane protein of coronaviruses and contains two subunits, S1 and S2. Among them, S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor angiotensin-converting enzyme 2 (ACE2). S2 contains the basic elements required for the membrane fusion process. The S protein has about 75% homology with SARS (68% homology with S1 and 94% homology with S2).
[0004] The antibodies usually detected in the novel coronavirus antibody test are IgG, IgM or total antibodies, and the methods usually used are the double antigen sandwich method or the indirect method / capture method. However, not all antibodies in IgG, IgM or total antibodies have a protective effect on the human body. The antibodies that have a protective effect on the human body are neutralizing antibodies (Neutralizing Antibody), which are produced in the blood of patients with novel coronavirus pneumonia a few days or about a week after infection. They can protect cells from damage by neutralizing or inhibiting the biological activity of the virus. Studies have shown that the S1 receptor binding domain (RBD) of the SARS-CoV-2 spike protein can interact with human ACE2, thereby infecting human respiratory epithelial cells, leading to endocytosis of host cells in the lungs and viral replication. It is an important site for host neutralizing antibodies and a key target for vaccine design. A large part of neutralizing antibodies are antibodies that prevent the binding of RBD protein to ACE2.
[0005] At present, SARS-CoV-2 virus infection has not been fully controlled worldwide, and nucleic acid testing has been widely used as the only gold standard for confirming infection. However, nucleic acid testing uses polymerase chain reaction (PCR) technology, which is much more complex than immunological testing methods, and nucleic acid testing is not easy to carry out in general laboratories.
[0006] Therefore, clinical laboratories are currently in urgent need of providing an in vitro diagnostic kit for serological detection of SARS-CoV-2 neutralizing antibodies. Summary of the invention
[0007] In view of the deficiencies in the prior art, the present invention provides a receptor reagent for detecting novel coronavirus neutralizing antibodies and its application. The detection of novel coronavirus antibodies using a kit containing the receptor reagent is simple to operate, has high sensitivity, specificity and accuracy, and can be used for batch and rapid detection of novel coronavirus neutralizing antibodies.
[0008] To this end, the first aspect of the present invention provides a receptor reagent for detecting neutralizing antibodies against the new coronavirus, which includes receptor microspheres that can react with active oxygen to produce detectable chemiluminescent signals, the interior of the receptor microspheres is filled with a chemiluminescent agent, and the surface of the receptor microspheres is connected to the new coronavirus RBD protein.
[0009] In some embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -5 mV and -60 mV.
[0010] In some preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -5.1 mV and -49.4 mV.
[0011] In some more preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -25.4 mV and -49.4 mV.
[0012] In some most preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -32.7 mV and -49.4 mV.
[0013] In some embodiments of the present invention, the surface of the receptor microspheres is coated with polysaccharides, the novel coronavirus RBD protein is connected to the polysaccharides, and the total sugar content per milligram of the receptor microspheres is not less than 25 micrograms; preferably, the total sugar content per milligram of the receptor microspheres is not less than 30 micrograms; further preferably, the total sugar content per milligram of the receptor microspheres is not less than 35 micrograms.
[0014] In other embodiments of the present invention, the sugar content is detected by anthrone method.
[0015] In some preferred embodiments of the present invention, the sugar is selected from carbohydrates containing three or more unmodified or modified monosaccharide units, preferably selected from dextran, starch, glycogen, inulin, fructan, mannan, agarose, galactan, carboxydextran and aminodextran; more preferably selected from dextran, starch, glycogen and polyribose.
[0016] In some embodiments of the present invention, the mass ratio of the receptor microspheres to the novel coronavirus RBD protein is 10:(0.3-0.6); preferably 10:(0.4-0.5).
[0017] In other embodiments of the present invention, the concentration of the receptor microsphere-new coronavirus RBD protein in the receptor reagent is 40-60 μg / mL; preferably 45-50 μg / mL.
[0018] The second aspect of the present invention provides a kit for detecting neutralizing antibodies of the new coronavirus, comprising:
[0019] Reagent 1, which is the receptor reagent as described in the first aspect of the present invention;
[0020] Reagent 2, which comprises a human ACE2 protein bound to one of the specific pair members.
[0021] In some embodiments of the present invention, the concentration of one of the specific pair members in the reagent 2 - human ACE2 protein is 0.3 to 0.6 μg / mL; preferably 0.4 to 0.5 μg / mL.
[0022] In some preferred embodiments of the present invention, the specific pairing member is selected from a pair of substances consisting of antibodies, antibody fragments, ligands, oligonucleotides, oligonucleotide binding proteins, lectins, haptens, antigens, immunoglobulin binding proteins, avidin, avidin or biotin; preferably, the specific pairing member is biotin-avidin.
[0023] In some specific embodiments of the present invention, the biotin is selected from biotin with different activation groups, preferably selected from biotin with NHS activation group that can react with amino group, and more preferably NHS-LC-LC-biotin.
[0024] The third aspect of the present invention provides a method for detecting novel coronavirus neutralizing antibodies in a sample using the kit as described in the second aspect of the present invention, comprising: by allowing the novel coronavirus neutralizing antibodies in the sample to be tested to bind to the acceptor microsphere-novel coronavirus RBD protein, thereby preventing the acceptor microsphere-novel coronavirus RBD protein from binding to one of the specific pairing members-human ACE2 protein, so that the complex of the acceptor microsphere-novel coronavirus RBD protein-human ACE2 protein-donor microsphere is reduced, thereby reducing the detectable chemiluminescent signal value generated by the reaction, and judging whether the novel coronavirus neutralizing antibodies are present in the sample to be tested according to the inhibition rate of the chemiluminescent signal value.
[0025] In some embodiments of the present invention, when the inhibition rate of the chemiluminescent signal value is ≥50%, the result is determined to be positive; when the inhibition rate of the chemiluminescent signal value is <50%, the result is determined to be negative.
[0026] The beneficial effects of the present invention are as follows: the present invention simulates the process of RBD protein entering the cell and adopts the principle of competition method to detect neutralizing antibodies. Human ACE2 is a conformation-dependent protein, and its binding site with the RBD protein is a conformational epitope. Conventional coating or labeling can easily change its conformation and make it inactive. The present invention adopts nano-photochemiluminescence method, by coating the RBD protein of the new coronavirus on the receptor microspheres, biotinylating the human ACE2 protein, so that the human ACE2 protein remains in the liquid phase, and giving it a suitable liquid phase environment, so that it can maintain its natural conformation as much as possible, thereby ensuring its activity. Compared with nucleic acid detection and ELISA detection, the receptor microsphere kit provided by the present invention has good sensitivity and specificity, high compliance of the detection results, and fast detection speed, reporting results within 30 minutes; the detection throughput is large, which can reach 200-500 tests / hour, which is suitable for large-scale sample detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to make the present invention easy to understand, the present invention is described below with reference to the accompanying drawings.
[0028] Figure 1 This is the standard curve for sugar content determination.
[0029] Figure 2 The figure shows the comparison of photochemiluminescence and ELISA signals for 120 nucleic acid-positive samples.
[0030] Figure 3 The graph shows the inhibition rate test results of samples at different dilutions in different periods, showing the trend comparison between photochemiluminescence and ELISA. DETAILED DESCRIPTION
[0031] To make the present invention easy to understand, the present invention will be described in detail below. However, before describing the present invention in detail, it should be understood that the present invention is not limited to the specific embodiments described. It should also be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting.
[0032] Where a numerical range is provided, it is understood that each intervening value between the upper and lower limits of the range and any other specified or intervening values in the specified range is encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges and are also encompassed within the present invention, subject to any explicitly excluded limits in the specified ranges. Where a specified range includes one or two limits, ranges excluding either or both of those included limits are also encompassed within the present invention.
[0033] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.
[0034] The present invention includes a kit of the receptor reagent, which simulates the process of RBD protein entering the cell, adopts the principle of competition method, and detects the neutralizing antibody of the new coronavirus by homogeneous chemiluminescence. Photochemiluminescence belongs to homogeneous chemiluminescence, which is a continuous chemical reaction and luminescent reaction process induced by light excitation. The donor microspheres and the acceptor microspheres can be close to each other by the combination of substances that can specifically bind, creating conditions for energy transfer, and generating light signals under laser irradiation. On the contrary, if the specific binding between substances does not occur, there will be a certain distance between the donor microspheres and the acceptor microspheres, and the acceptor microspheres do not meet the conditions for receiving energy-induced luminescence, so no light signal is generated. Therefore, without separation and washing, the light signal is directly detected, and the intensity of the light signal is positively correlated with the specific binding between substances. Photochemiluminescence analysis is a homogeneous luminescent immunoassay, a trace material quantitative analysis technology established based on the principle of photochemiluminescence and specific binding between substances. There is no separation or washing process in the whole process, which is simple and fast. It is characterized by the unique "double balls" and "double labels" method. The solid phase microspheres have good suspension performance, which is more conducive to the uniform diffusion of the microspheres, as well as the mutual collision and binding of the antigen molecules on the surface of the microspheres with the antibodies or receptor proteins to be tested.
[0035] In the kit of the present invention, firstly, RBD protein and human ACE2 protein are selected to be coated with receptor microspheres (FG-Ag) and biotin (Bio-Ag) (one of the specific pairing members), respectively, as receptor reagent (reagent 1) and capture reagent (reagent 2); avidin (another member of the specific pairing member) is used to coat the donor microspheres as a universal solution (donor reagent). Secondly, reagent 1 and reagent 2, as well as the sample to be tested and the quality control product are added to the microwells respectively, and after starting the first stage of warm bath, a receptor microsphere-new coronavirus RBD protein-human ACE2 protein-biotin complex is formed on the surface of the receptor microsphere; the universal solution is directly added without washing, and the second stage of warm bath is started, biotin binds to avidin, and the two microspheres are close to each other; at this time, a laser beam is used to excite and induce a photoinduced chemiluminescence reaction to produce a light signal. After the sample to be tested is added, if the sample to be tested contains neutralizing antibodies against the new coronavirus, the neutralizing antibodies against the new coronavirus in the sample to be tested will bind to the acceptor microsphere-new coronavirus RBD protein, thereby preventing the binding of the acceptor microsphere-new coronavirus RBD protein with biotin-human ACE2 protein, thereby reducing the complex of the acceptor microsphere-new coronavirus RBD protein-human ACE2 protein-donor microsphere, thereby causing the detectable chemiluminescence signal value generated by the reaction to be lower than that of the negative sample.
[0036] Therefore, the receptor reagent for detecting novel coronavirus neutralizing antibodies involved in the first aspect of the present invention includes receptor microspheres that can react with active oxygen to produce detectable chemiluminescent signals, wherein the interior of the receptor microspheres is filled with a chemiluminescent agent, and the surface of the receptor microspheres is connected to the novel coronavirus RBD protein (i.e., receptor microsphere-novel coronavirus RBD protein).
[0037] The term "neutralizing antibody" mentioned in the present invention has the function of recognizing the receptor binding domain RBD of the spike protein S on the surface of the new coronavirus and blocking its binding to angiotensin-converting enzyme 2 (ACE2) on the cell surface.
[0038] The term "acceptor microspheres" used in the present invention refers to microspheres containing compounds that can react with active oxygen to produce detectable signals. Donor microspheres are activated by energy or active compounds and release high-energy active oxygen, which is captured by receptor particles at a close distance, thereby transferring energy to activate the receptor microspheres. The receptor microspheres can have different functional groups, such as aldehyde groups, carboxyl groups, amino groups, etc., preferably aldehyde receptor microspheres and carboxyl receptor microspheres that can couple with free amino groups of proteins, and more preferably aldehyde receptor microspheres.
[0039] In other embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -5mV and -60mV potential. In some specific embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent can be -5mV, -5.1mV, -10mV, -15mV, -20mV, -25.4mV, -30mV, -32.7mV, -40mV, -49.4mV, -50mV or -60mV, etc. In some preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -5.1mV and -49.4mV potential. In some more preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -25.4mV and -49.4mV potential. In some most preferred embodiments of the present invention, the Zeta potential of the receptor microspheres in the receptor reagent is between -32.7mV and -49.4mV potential. The inventors of the present application have found that precisely controlling the Zeta potential of the receptor microspheres in the receptor reagent within an appropriate range can make the kit have the advantages of strong anti-interference ability and good test performance.
[0040] The Zeta potential value described in the present invention refers to the potential value of the receptor microspheres in a dispersed system with a pH of 6 to 9. The Zeta potential of the microspheres refers to the potential of the microspheres at the shear surface; that is, the potential difference between the continuous phase and the stable layer of the fluid attached to the microspheres. Since the surface of the dispersed particles carries an electric charge, it attracts the surrounding counter-ions, and these counter-ions are distributed in a diffuse state at the interface of the two phases to form a diffuse double layer. According to the Stern double layer theory, the double layer can be divided into two parts, namely the Stern layer and the diffuse layer. The Stern layer is defined as a planar layer composed of a layer of ion (IHP or OHP) charge centers adsorbed on the surface of the electrode. The potential of this planar layer relative to a point in the fluid far away from the interface is called the Stern potential. The interface between the stationary layer (including the Stern layer and the diffusion layer within the slipping plane) and the dispersion medium in the diffusion layer when they move relative to each other is the slipping plane. The potential at this point to a point in the fluid far away from the interface is called the Zeta potential or electrokinetic potential (ζ-potential), that is, the Zeta potential is the potential difference between the continuous phase and the stationary layer of the fluid attached to the dispersed particles. It can be directly measured by electrokinetic phenomena. At present, the main methods for measuring Zeta potential are electrophoresis, electroosmosis, streaming potential and ultrasonic method, among which electrophoresis is the most widely used.
[0041] The term "active oxygen" as used herein refers to a general term for substances in the body or natural environment that are composed of oxygen, contain oxygen and are active in nature, mainly an excited oxygen molecule, including superoxide anion (O2·-), a one-electron reduction product of oxygen, hydrogen peroxide (H2O2), a three-electron reduction product of oxygen, hydroxyl radical (·OH), as well as nitric oxide and singlet oxygen (1O2), etc. In some specific embodiments of the present invention, the active oxygen may be singlet oxygen.
[0042] In some embodiments of the present invention, the receptor microspheres have functional groups on their surfaces; preferably, the functional groups are selected from at least one of aldehyde, carboxyl and amino groups; more preferably, they are aldehyde and / or carboxyl; and even more preferably, they are aldehyde groups.
[0043] In other embodiments of the present invention, the surface of the receptor microspheres is coated with polysaccharides, the novel coronavirus RBD protein is connected to the polysaccharides, and the total sugar content per milligram of the receptor microspheres is not less than 25 micrograms.
[0044] In some preferred embodiments of the present invention, the total sugar content of the acceptor microspheres is not less than 30 micrograms per milligram; preferably, the total sugar content of the acceptor microspheres is not less than 35 micrograms per milligram.
[0045] In some specific embodiments of the present invention, the total sugar content per mg of the acceptor microspheres can be 25 μg, 30 μg, 35 μg, 40 μg, 49 μg, 50 μg, 80 μg, 100 μg, 150 μg or 200 μg, etc.
[0046] In some embodiments of the present invention, the sugar content is detected by anthrone method.
[0047] In some preferred embodiments of the present invention, the sugar is selected from carbohydrates containing three or more unmodified or modified monosaccharide units, preferably selected from dextran, starch, glycogen, inulin, fructan, mannan, agarose, galactan, carboxydextran and aminodextran; more preferably selected from dextran, starch, glycogen and polyribose.
[0048] In some embodiments of the present invention, the mass ratio of the receptor microspheres to the novel coronavirus RBD protein is 10:(0.3-0.6); preferably 10:(0.4-0.5); and more preferably 10:0.4.
[0049] In some specific embodiments of the present invention, the receptor reagent further comprises a buffer, and the receptor microspheres are suspended in the buffer.
[0050] In some embodiments of the present invention, the concentration of the receptor microsphere-new coronavirus RBD protein in the receptor reagent is 40-60 μg / mL; preferably 45-50 μg / mL; more preferably 50 μg / mL.
[0051] The second aspect of the present invention provides a kit for detecting neutralizing antibodies of the new coronavirus, comprising:
[0052] Reagent 1, which is the receptor reagent as described in the first aspect of the present invention;
[0053] Reagent 2, which comprises a human ACE2 protein bound to a member of a specific pairing member (ie, a member of a specific pairing member - a human ACE2 protein).
[0054] In some specific embodiments of the present invention, the reagent 2 further comprises a buffer, and the human ACE2 protein bound to one of the specific pairing members is dispersed in the buffer.
[0055] In some embodiments of the present invention, the concentration of one of the specific pair members in the reagent 2 - human ACE2 protein is 0.3-0.6 μg / mL; preferably 0.4-0.5 μg / mL; more preferably 0.5 μg / mL.
[0056] In some specific embodiments of the present invention, the kit may further include a donor reagent, which includes donor microspheres, and the donor microspheres are capable of generating reactive oxygen species under excitation; preferably, the donor reagent is combined with another member of the specific pairing member.
[0057] The term "donor microsphere" as used herein refers to a microsphere containing a sensitizer that can produce an active intermediate such as active oxygen that reacts with the acceptor microsphere after being activated by energy or an active compound. The donor microsphere can be photoactivated (such as dyes and aromatic compounds) or chemically activated (such as enzymes, metal salts, etc.). In some specific embodiments of the present invention, the donor microsphere is a polymer microsphere filled with a photosensitizer, and the photosensitizer can be a photosensitizer known in the art, preferably a compound that is relatively stable to light and does not effectively react with singlet oxygen, and its non-limiting examples include compounds such as methylene blue, rose bengal, porphyrin, phthalocyanine and chlorophyll disclosed in U.S. Pat. No. 5,709,994 (the entire text of this patent document is cited herein as a reference), and derivatives of these compounds having 1-50 atomic substituents, the substituents are used to make these compounds more lipophilic or more hydrophilic, and / or as a linking group connected to a specific binding pair member. Examples of other photosensitizers known to those skilled in the art can also be used in the present invention, such as those described in U.S. Pat. No. 6,406,913, which is incorporated herein by reference.
[0058] The term "specific pair members" used in the present invention refers to a pair of substances that can specifically bind to each other. The term "specific binding" used in the present invention refers to the mutual recognition and selective binding reaction between two substances, which is the correspondence of the conformations between the corresponding reactants from the perspective of stereostructure.
[0059] In some specific embodiments of the present invention, the specific pairing member is selected from a pair of substances consisting of antibodies, antibody fragments, ligands, oligonucleotides, oligonucleotide binding proteins, lectins, haptens, antigens, immunoglobulin binding proteins, avidin, avidin or biotin; preferably, the specific pairing member is biotin-avidin.
[0060] The term "biotin" used in the present invention is widely present in animal and plant tissues. Its molecule has two ring structures, namely, imidazolone ring and thiophene ring, wherein the imidazolone ring is the main site for binding with streptavidin. Activated biotin can be coupled with almost all known biological macromolecules, including proteins, nucleic acids, polysaccharides and lipids, under the mediation of protein cross-linking agents. The "avidin" molecule is composed of 4 identical peptide chains, each of which can bind to one biotin. Therefore, each antigen or antibody can be coupled with multiple biotin molecules at the same time, thereby producing a "tentacle effect" to improve the sensitivity of analysis.
[0061] In some specific embodiments of the present invention, the biotin is selected from biotin with different activation groups, preferably selected from biotin with NHS activation group that can react with amino group, and more preferably NHS-LC-LC-biotin.
[0062] The third aspect of the present invention provides a method for detecting novel coronavirus neutralizing antibodies in a sample using the kit as described in the second aspect of the present invention, comprising: by allowing the novel coronavirus neutralizing antibodies in the sample to be tested to bind to the acceptor microsphere-novel coronavirus RBD protein, thereby preventing the acceptor microsphere-novel coronavirus RBD protein from binding to one of the specific pairing members-human ACE2 protein, so that the complex of the acceptor microsphere-novel coronavirus RBD protein-human ACE2 protein-donor microsphere is reduced, thereby making the detectable chemiluminescent signal value generated by the reaction lower than the chemiluminescent signal value of the negative control sample, and judging whether the novel coronavirus neutralizing antibodies are present in the sample to be tested according to the inhibition rate of the chemiluminescent signal value.
[0063] In some embodiments of the present invention, the method specifically comprises the following steps:
[0064] S1, mixing a sample to be tested, reagent 1 and reagent 2 to obtain a first mixture;
[0065] S2, mixing the donor reagent with the first mixture to obtain a second mixture;
[0066] S3, treating the second mixture with energy or an active compound to excite the donor microspheres to generate reactive oxygen species, and the acceptor reacts with the reactive oxygen species to generate a detectable chemiluminescent signal;
[0067] S4, judging whether there are novel coronavirus neutralizing antibodies in the sample to be tested based on the inhibition rate of the chemiluminescence signal value.
[0068] In some embodiments of the present invention, when the inhibition rate of the chemiluminescent signal value is ≥50%, the result is judged as positive, that is, the test result is that the sample to be tested contains new coronavirus neutralizing antibodies; when the inhibition rate of the chemiluminescent signal value is <50%, the result is judged as negative, that is, the test result is that the sample to be tested does not contain new coronavirus neutralizing antibodies.
[0069] In the present invention, the inhibition rate of the chemiluminescent signal value = (negative control signal - test sample signal) / negative control signal.
[0070] In the method of the present invention, the reagents can be incubated as needed after mixing. Specifically, the incubation temperature can be 35-40°C, and the time can be 10-20 minutes; preferably, the incubation temperature can be selected from 36°C, 37°C, 38°C, 39°C or 40°C; the incubation time can be selected from 10 minutes, 12 minutes, 15 minutes, 18 minutes or 20 minutes; more preferably, the incubation temperature is 37°C, the incubation time of step S1 is 15 minutes, and the incubation time of step S2 is 10 minutes.
[0071] In the present invention, the sample to be tested, the receptor reagent and the capture reagent are each independently added in an amount of 15-35uL; preferably, the sample to be tested, the receptor reagent and the capture reagent are each independently added in an amount of 15uL, 18uL, 20uL, 22uL, 25uL, 28uL, 30uL or 35uL. More preferably, the sample to be tested, the receptor reagent and the capture reagent are each added in an amount of 25uL.
[0072] Example
[0073] In order to make the present invention easier to understand, the present invention will be further described in detail below in conjunction with examples, which are merely illustrative and are not intended to limit the scope of application of the present invention. The raw materials or components used in the present invention can be obtained by commercial routes or conventional methods unless otherwise specified.
[0074] Example 1: Preparation of acceptor microspheres
[0075] 1.1 Synthesis of aldehyde-based polystyrene latex microspheres
[0076] Prepare a 100ml three-necked flask, add 40mmol styrene, 5mmol acrolein, and 10ml water, stir for 10min, and then pass N2 for 30min;
[0077] 1) Weigh 0.11 g of ammonium persulfate and 0.2 g of sodium chloride, dissolve in 40 ml of water to prepare an aqueous solution. Add the aqueous solution to the reaction system in step 1) and continue to pass N2 for 30 min;
[0078] 2) The reaction system was heated to 70°C and reacted for 15 hours;
[0079] 3) After the reaction is completed, the emulsion is cooled to room temperature and filtered with a suitable filter cloth. The obtained emulsion is washed with deionized water by centrifugal sedimentation for multiple times until the conductivity of the supernatant at the beginning of the centrifugation is close to that of deionized water, and then diluted with water and stored in the form of an emulsion.
[0080] 1.2. Filling process and characterization of luminescent composition
[0081] 1) Prepare a 25 ml round-bottom flask, add 0.1 g of dimethylthiophene derivative and 0.1 g of europium (III) complex (MTTA-EU 3+ ), 10 ml of 95% ethanol, magnetic stirring, and heating to 70°C in a water bath to obtain a complex solution;
[0082] 2) Prepare a 100 ml three-necked flask, add 10 ml of 95% ethanol, 10 ml of water and 10 ml of 10% aldehyde-based polystyrene latex microspheres obtained in step 1.1, stir magnetically, and heat the water bath to 70°C;
[0083] 3) slowly dropwise adding the complex solution in step 1) into the three-necked flask in step 2), reacting at 70° C. for 2 hours, then stopping stirring and cooling naturally;
[0084] 4) The emulsion was centrifuged at 30000G for 1 hour, and the supernatant was discarded to obtain aldehyde-based polystyrene microspheres filled with chemiluminescent agent.
[0085] 1.3 Surface coating of receptor particles with dextran
[0086] 1) Take 50 mg of aminodextran solid in a 20 mL round-bottom flask, add 5 mL of 50 mM / pH=10 carbonate buffer, stir and dissolve at 30°C in the dark;
[0087] 2) taking 100 mg of the prepared aldehyde-based polystyrene microspheres filled with the luminescent composition, adding them to the aminodextran solution and stirring for 2 h;
[0088] 3) Dissolve 10 mg of sodium borohydride in 0.5 mL of 50 mM / pH = 10 carbonate buffer and add dropwise to the above reaction solution. React at 30° C. in the dark overnight.
[0089] 4) After the reaction mixture was centrifuged at 30000G, the supernatant was discarded, and 50mM / pH=10 carbonate buffer was added for ultrasonic dispersion. After repeated centrifugation and washing three times, the volume was fixed with 50mM / pH=10 carbonate buffer to a final concentration of 20mg / mL;
[0090] 5) Take 100 mg of aldehyde dextran solid in a 20 mL round-bottom flask, add 5 mL of 50 mM / pH = 10 carbonate buffer, stir and dissolve at 30 ° C in the dark;
[0091] 6) Add the above microspheres to the aldehyde dextran solution and stir for 2 hours;
[0092] 7) Dissolve 15 mg of sodium borohydride in 0.5 mL of 50 mM / pH = 10 carbonate buffer and add dropwise to the above reaction solution. React at 30° C. in the dark overnight;
[0093] 8) The reaction mixture was centrifuged at 30000G, the supernatant was discarded, and 50mM / pH=10 carbonate buffer was added for ultrasonic dispersion. The centrifugation was repeated three times, and the volume was fixed with 50mM / pH=10 carbonate buffer to a final concentration of 20mg / mL.
[0094] 9) The Gaussian distribution average particle size of the microspheres measured by a nanoparticle size analyzer is 241.6 nm, and the coefficient of variation (CV) is 12.90%.
[0095] Example 2: Preparation of receptor microspheres-new coronavirus RBD protein
[0096] 1) Pretreatment: Add the 2019-nCoV RBD protein to be dialyzed into a dialysis bag (3.5KD), clamp the dialysis bag, and place it in dialysis buffer for dialysis. Stir magnetically at 2-8°C for at least 4 hours, and change the solution at least twice in the middle. The volume of the dialysate each time should be no less than 100 times the volume of the dialyzate.
[0097] 2) Protein concentration determination: The dialyzed protein was aspirated and transferred to a clean centrifuge tube, and the protein concentration was determined using a BCA protein assay kit.
[0098] Coating process:
[0099] 1) Cleaning: According to the planned production volume, take the blank receptor microspheres prepared in Example 1 into a centrifuge tube and add coating buffer (1 mL of coating buffer per 10 mg of receptor microspheres). Place in a high-speed refrigerated centrifuge at 2-8°C, 8000rpm, centrifuge for 20 minutes, and discard the supernatant. Add coating buffer (1 mL of coating buffer per 10 mg of receptor microspheres) to the centrifuge tube and sonicate until no visible solid suspended particles are present. Repeat the above steps (centrifugation, removing the supernatant) once.
[0100] 2) Coating: Mix the treated receptor microspheres and the treated 2019-nCoV RBD protein (the mass ratio of receptor microspheres to 2019-nCoV RBD protein is 10:0.4, and use coating buffer to make the volume to 20 mg / mL (receptor microsphere concentration). After ultrasonic dispersion, place the mixture in a multi-tube adjustable rotary mixer in a constant temperature incubator at room temperature, 25-40 rpm, and mix for 14-18 hours.
[0101] 3) Reduction: Rapidly add the prepared reducing agent solution (20 μL per 10 mg of acceptor microspheres) and react for 2 hours in a multi-tube adjustable rotary mixer at 2-8° C. and 25-40 rpm.
[0102] 4) Blocking: Take a blocking agent solution (160 μL per 10 mg of receptor microspheres), add it to the reaction solution, and react for 1 hour at 2-8° C. and 25-40 rpm in a multi-tube adjustable rotary mixer.
[0103] 5) Cleaning: Add luminescent cleaning solution to the coated receptor microspheres (1 mL of luminescent cleaning solution for every 10 mg of receptor microspheres), place the centrifuge tube in a high-speed refrigerated centrifuge at 2-8°C, 8000 rpm, centrifuge for 20 minutes, and discard the supernatant. Add luminescent cleaning solution to the centrifuge tube and sonicate until no visible solid suspended particles are present. Repeat the above steps (centrifugation, discard the supernatant) once. Add luminescent reagent buffer I to each centrifuge tube (1 mL of liquid for every 10 mg of receptor microspheres) and disperse by sonication. Place the centrifuge tube in a high-speed refrigerated centrifuge at 2-8°C, 8000 rpm, centrifuge for 20 minutes, and discard the supernatant.
[0104] 7) Volume adjustment: Add luminescent reagent buffer I to each centrifuge tube, dilute the acceptor microspheres to 10 mg / mL, and disperse them by ultrasonication until no suspended particles are visible.
[0105] 8) Storage: Transfer the fixed volume liquid into a brown plastic bottle, divide and label it, and store it at 2-8°C for later use to obtain receptor microspheres-new coronavirus RBD protein.
[0106] Example 3: Preparation of biotin-human ACE2
[0107] 1) Human ACE2 dialysis: Add the human ACE2 to be dialyzed into a dialysis bag (3.5KD), clamp the dialysis bag, and place it in a biotin-labeled buffer for dialysis. Stir magnetically at 2-8°C for at least 4 hours, and change the solution at least twice in the middle. The dialysate volume each time should be no less than 100 times the volume of the dialyzate.
[0108] 2) Protein concentration determination: The dialyzed protein was aspirated and transferred to a clean centrifuge tube, and the protein concentration was determined using a BCA protein assay kit.
[0109] 3) Labeling reaction: Weigh biotin and dissolve it in DMSO to a concentration of 5 mg / mL. Take the treated human ACE2 and the prepared biotin solution, mix them according to the ratio (add 18 μL of 5 mg / mL biotin solution for every 1 mg of human ACE2), and mix them quickly. Mix at 2-8°C and react at 25-40rpm for 14-18 hours.
[0110] 4) Dialysis: Add the above reaction solution into a dialysis bag (3.5KD), clamp the dialysis bag, and place it into biotin-labeled dialysis buffer for dialysis. Stir magnetically at 2-8°C for not less than 4 hours. Change the solution at least twice in the middle, and the volume of the dialysate each time should be not less than 100 times the volume of the dialyzate.
[0111] 5) Protein concentration determination: The dialyzed protein was aspirated and transferred to a clean centrifuge tube, and the protein concentration was determined using a BCA protein assay kit.
[0112] 6) Storage: Add an equal volume of glycerol and store at ≤-15°C, aliquot and label to obtain biotin-human ACE2.
[0113] Example 4: Preparation of kit
[0114] Reagent 1: Use diluent to dilute the receptor microspheres-new coronavirus RBD protein to 50μg / mL to obtain reagent 1;
[0115] Reagent 2: Use diluent to dilute biotin-human ACE2 protein to 0.5 μg / mL to obtain reagent 2.
[0116] Example 5: Detection of sugar content of acceptor microspheres
[0117] 1) Pretreatment of receptor microsphere samples:
[0118] Reagent 1 containing 1 mg of receptor microspheres-new coronavirus RBD protein in Example 4 was taken separately, centrifuged at 20000G for 40 min, the supernatant was poured off and ultrasonically dispersed with purified water, and the centrifugal dispersion was repeated three times and then fixed to 1 mg / mL with purified water to obtain the sample to be tested.
[0119] 2) Preparation of glucose standard solution:
[0120] Use purified water to prepare 1 mg / mL glucose stock solution into 0 mg / mL, 0.025 mg / mL, 0.05 mg / mL, 0.075 mg / mL, 0.10 mg / mL, and 0.15 mg / mL standard solutions.
[0121] 3) Preparation of anthrone solution: Prepare 2 mg / mL with 80% sulfuric acid solution (this solution is stable at room temperature for 24 hours and should be prepared immediately before use).
[0122] 4) Add 0.1 mL of glucose standard solution of each concentration and the sample to be tested to the centrifuge tubes respectively, and add 1 mL of anthrone test solution to each tube.
[0123] 5) Incubate at 85°C for 30 min.
[0124] 6) Centrifuge the sample reaction tube at 15000G for 40 minutes, and use a pipette tip to aspirate the clear liquid from the bottom of the tube to measure the absorbance, avoiding aspirating the suspended matter on the top.
[0125] 7) Return to room temperature and measure the absorbance at 620 nm (measurement should be performed preferably within 2 hours).
[0126] 8) The relationship between the sugar content concentration and absorbance of the standard solution is shown in Table 1. With the sugar content concentration of the standard solution as the X value and the absorbance as the Y value, a linear regression is performed to obtain the following: Figure 1 The sugar content concentration of the sample to be tested was determined based on the sugar content determination standard curve shown.
[0127] Table 1
[0128] Serial number Concentration mg / mL Absorbance A Absorbance B Absorbance mean 1 0.15 0.415 0.411 0.4130 2 0.1 0.293 0.302 0.2975 3 0.075 0.214 0.227 0.2205 4 0.05 0.146 0.153 0.1495 5 0.025 0.101 0.098 0.0995 6 0 0.032 0.031 0.0315
[0129] The test results showed that the sugar content of the acceptor microspheres was 49 μg / mg microspheres.
[0130] Example 6: Method for using the kit of the present invention
[0131] 1) Add 25uL of the sample to be tested, 25uL of reagent 1 and 25uL of reagent 2 to the microplate at 37°C
[0132] Incubate for 15 min;
[0133] 3) Add 175uL of universal solution (donor reagent) for photochemiluminescence analysis system, incubate at 37℃ for 15min, and use HT for reading.
[0134] Example 7: Determination of Zeta Potential of Acceptor Microspheres in Reagent 1
[0135] The Zeta potential of reagent 1 was measured by using a NICOMP 380Z3000 instrument after calibration with a standard, and a series of reagents 1 with different Zeta potentials were prepared. Then, the same batch of samples were tested in each kit using the method shown in Example 6. The signal levels were compared on the HT photochemiluminescence instrument and the results are shown in Table 2.
[0136] Table 2
[0137]
[0138] The results showed that the average level of the on-machine detection signal of the receptor microspheres in reagent 1 was higher when the Zeta potential was between -5mV and -60mV, and the average level of the on-machine detection signal was even higher when the Zeta potential was between -25mV and -50mV.
[0139] Example 8: Real sample detection
[0140] Taking the positive nucleic acid of the new coronavirus as the standard, this kit was used to detect 120 samples of positive nucleic acid of the new coronavirus (the detection result judgment standard is that the inhibition rate of the signal value is ≥50% as positive, and <50% as negative). As a result, 112 samples were detected as positive, 8 samples were detected as negative, and the sensitivity was 93.3%. The test results are shown in Table 3; 100 negative samples were tested, and the results showed that 0 samples were positive, 100 samples were negative, and the specificity was 99%. The test results are shown in Table 4.
[0141] This kit and the GenScript ELISA kit were used to simultaneously test 120 novel coronavirus nucleic acid-positive samples, and the test results were compared (see Table 3) (the GenScript ELISA result judgment standard is that the inhibition rate of the OD value is ≥ 20% to be positive, and < 20% to be positive); the statistical test results of positive and negative coincidence rates are both 100% (see Table 5). The OD value of GenScript ELISA is the horizontal axis, Plot the signal value as the ordinate, and we get The correlation coefficient (R) between the signal value and the OD value of GenScript ELISA was 0.973 (see Figure 2 ).
[0142] Table 3: Test results of 120 nucleic acid positive samples
[0143]
[0144]
[0145]
[0146]
[0147] Table 4: Test results of 100 nucleic acid negative samples
[0148]
[0149]
[0150]
[0151]
[0152] Table 5: GenScript ELISA and The positive and negative coincidence rates
[0153]
[0154] From the positive samples, one portion of each sample from different sample retention periods was selected and diluted 0, 10, 100, and 1000 times, respectively. Each sample was tested simultaneously with this kit and GenScript ELISA kit. The test results are shown in Table 6. The Log value of the dilution multiple was plotted as the horizontal axis and the inhibition rate as the vertical axis. The results showed that samples from different periods, The trend of the platform in detecting novel coronavirus neutralizing antibodies is close to that of GenScript ELISA (see Figure 3 ).
[0155] Table 6: Inhibition of samples at different times
[0156]
[0157]
[0158] It should be noted that the embodiments described above are only used to explain the present invention and do not constitute any limitation to the present invention. The present invention has been described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present invention may be modified as specified within the scope of the claims of the present invention, and the present invention may be revised without departing from the scope and spirit of the present invention. Although the present invention described therein relates to specific methods, materials and embodiments, it does not mean that the present invention is limited to the specific examples disclosed therein, on the contrary, the present invention can be extended to all other methods and applications with the same functions.
Claims
1. A receptor reagent for detecting a novel coronavirus neutralizing antibody, comprising a receptor microsphere capable of reacting with reactive oxygen to produce a detectable chemiluminescent signal; the interior of the receptor microsphere is filled with a chemiluminescent agent, and the surface of the receptor microsphere is connected to a novel coronavirus RBD protein; The Zeta potential of the receptor microspheres in the receptor reagent is between -5mV and -60mV; The surface of the receptor microspheres is coated with polysaccharides, the novel coronavirus RBD protein is connected to the polysaccharides, and the total sugar content per milligram of the receptor microspheres is not less than 25 micrograms.
2. The receptor reagent according to claim 1, It is characterized in that The Zeta potential of the receptor microspheres in the receptor reagent is between -5.1 mV and -49.4 mV.
3. The receptor reagent according to claim 1, It is characterized in that The Zeta potential of the receptor microspheres in the receptor reagent is between -25.4 mV and -49.4 mV.
4. The receptor reagent according to claim 1, It is characterized in that The Zeta potential of the receptor microspheres in the receptor reagent is between -32.7 mV and -49.4 mV.
5. The receptor reagent according to any one of claims 1 to 4, It is characterized in that The total sugar content of each milligram of the acceptor microspheres is not less than 30 micrograms.
6. The receptor reagent according to claim 5, It is characterized in that The total sugar content of each milligram of the acceptor microspheres is not less than 35 micrograms.
7. The receptor reagent according to claim 1, It is characterized in that The sugar content was detected by the anthrone method.
8. The receptor reagent according to claim 7, It is characterized in that The sugar is selected from carbohydrates containing three or more unmodified or modified monosaccharide units.
9. The receptor reagent according to claim 8, It is characterized in that The sugar is selected from the group consisting of dextran, starch, glycogen, inulin, fructan, mannan, agarose, galactan, carboxydextran and aminodextran.
10. The receptor reagent according to claim 9, It is characterized in that The sugar is selected from the group consisting of dextran, starch, glycogen and polyribose.
11. The receptor reagent according to claim 1, It is characterized in that The mass ratio of the receptor microspheres to the new coronavirus RBD protein is 10: (0.3~0.6).
12. The receptor reagent according to claim 11, It is characterized in that The mass ratio of the receptor microspheres to the new coronavirus RBD protein is 10:(0.4~0.5).
13. The receptor reagent according to claim 1, It is characterized in that The concentration of the receptor microsphere-new coronavirus RBD protein in the receptor reagent is 40-60 μg / mL.
14. The receptor reagent according to claim 13, It is characterized in that The concentration of the receptor microsphere-new coronavirus RBD protein in the receptor reagent is 45~50μg / mL.
15. A kit for detecting neutralizing antibodies of novel coronavirus, include: Reagent 1, which is a receptor reagent as claimed in any one of claims 1 to 14; Reagent 2, comprising a human ACE2 protein bound to one of the specific pair members; A donor agent, wherein the donor microsphere is capable of generating reactive oxygen species in an excited state, and the donor agent is combined with the other member of the specific pair.
16. The kit according to claim 15, It is characterized in that The concentration of one of the specific pairing members in the reagent 2 - human ACE2 protein is 0.3~0.6μg / mL.
17. The kit according to claim 16, It is characterized in that The concentration of one of the specific pairing members in the reagent 2 - human ACE2 protein is 0.4~0.5μg / mL.
18. The kit according to claim 15 or 16, It is characterized in that The specific pairing member is selected from a pair of substances consisting of antibodies, antibody fragments, ligands, oligonucleotides, oligonucleotide binding proteins, lectins, haptens, antigens, immunoglobulin binding proteins, avidin, avidin or biotin.
19. The kit according to claim 18, It is characterized in that The specific pair member is biotin-avidin.
20. The kit according to claim 19, It is characterized in that The biotin is selected from biotin with different activated groups.
21. The kit according to claim 20, It is characterized in that The biotin is selected from biotin with an NHS activation group that can react with an amino group.
22. The kit according to claim 21, It is characterized in that The biotin is NHS-LC-LC-biotin.
Citation Information
Patent Citations
Photoactivatable chemiluminescent matrices
US5709994A
Assay method utilizing induced luminescence
US6406913B1
Light-activating chemiluminescence immunoassay kit for serum specific IgE (immunoglobulin E)
CN105785030A
Immunochromatography kit for fluorescent quantitative detection of hog cholera virus neutralizing antibody
CN106290868A
Homogeneous immunoassay kit for detecting target anti-Carp antibodies and application thereof
CN108445223A
